Literature DB >> 3089026

Platelet-activating factor and the kidney.

D Schlondorff, R Neuwirth.   

Abstract

Platelet-activating factor (PAF) represents a group of phospholipids with the basic structure of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. A number of different cells are capable of producing PAF in response to various stimuli. The initial step of PAF formation is activation of phospholipase A2 in a calcium-dependent manner, yielding lyso-PAF. During this step arachidonic acid is also released and can be converted to its respective cyclooxygenase and lipoxygenase products. The lyso-PAF generated is then acetylated in position 2 of the glycerol backbone by a coenzyme A (CoA)-dependent acetyltransferase. An additional pathway may exist whereby PAF is generated de novo from 1-alkyl-2-acetyl-sn-glycerol by phosphocholine transferase. PAF inactivation in cells and blood is by specific acetylhydrolases. PAF exhibits a variety of biological activities including platelet and leukocyte aggregation and activation, increased vascular permeability, respiratory distress, decreased cardiac output, and hypotension. In the kidney PAF can produce decreases in blood flow, glomerular filtration, and fluid and electrolyte excretion. Intrarenal artery injection of PAF may also result in glomerular accumulation of platelets and leukocytes and mild proteinuria. PAF increases prostaglandin formation in the isolated kidney and in cultured glomerular mesangial cells. PAF also causes contraction of mesangial cells. Upon stimulation with calcium ionophore the isolated kidney, isolated glomeruli and medullary cells, and cultured mesangial cells are capable of producing PAF. The potential role for PAF in renal physiology and pathophysiology requires further investigation that may be complicated by 1) the multiple interactions of PAF, prostaglandins, and leukotrienes and 2) the autocoid nature of PAF, which may restrict its action to its site of generation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089026     DOI: 10.1152/ajprenal.1986.251.1.F1

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  18 in total

Review 1.  Paracrine and autocrine functions of glomerular mesangial cells.

Authors:  P Menè; G A Cinotti
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

2.  Effect of platelet-activating factor on cortisol and corticosterone secretion by perfused dog adrenal.

Authors:  T Aikawa; T Hirose; I Matsumoto; T Morikawa; T Shimada; Y Mine; Y Tsujimoto; Y Tsuji
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Renal haemodynamics and prostaglandin synthesis in partial unilateral ureteric obstruction.

Authors:  S J Sheehan; K T Moran; D J Dowsett; J M Fitzpatrick
Journal:  Urol Res       Date:  1994

Review 4.  Role of platelets in progressive glomerular diseases.

Authors:  C Zoja; G Remuzzi
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

5.  Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis.

Authors:  Matheus Correa-Costa; Vinicius Andrade-Oliveira; Tarcio T Braga; Angela Castoldi; Cristhiane F Aguiar; Clarice S T Origassa; Andrea C D Rodas; Meire I Hiyane; Denise M A C Malheiros; Francisco J O Rios; Sonia Jancar; Niels O S Câmara
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

6.  Changes in ether-linked phospholipids in rat kidney by dietary alpha-linolenic acid in vivo.

Authors:  J H Park; E J Park; K S Kim; Y K Yeo
Journal:  Lipids       Date:  1995-06       Impact factor: 1.880

Review 7.  The role of platelet-activating factor (PAF) in experimental glomerular injury.

Authors:  A Ortiz; M Gomez-Chiarri; J L Lerma; E Gonzalez; J Egido
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Synthesis of a PAF immunogen and production of PAF-specific antibodies.

Authors:  M A Smal; B A Baldo; J W Redmond
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

9.  Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane.

Authors:  O F dos Santos; M A Boim; E J Barros; E Pirotzky; P Braquet; N Schor
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

10.  Inhibitor(s) of platelet-activating factor (PAF) in human saliva.

Authors:  M A Smal; B A Baldo
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.